- Home
- FGEN vs LSTA Comparison
FGEN vs LSTA Comparison
Compare FGEN & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- LSTA
- Stock Information
- Founded
- FGEN 1993
- LSTA 1980
- Country
- FGEN United States
- LSTA United States
- Employees
- FGEN N/A
- LSTA N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- LSTA Misc Health and Biotechnology Services
- Sector
- FGEN Health Care
- LSTA Health Care
- Exchange
- FGEN Nasdaq
- LSTA Nasdaq
- Market Cap
- FGEN 33.5M
- LSTA 22.5M
- IPO Year
- FGEN 2014
- LSTA N/A
- Fundamental
- Price
- FGEN $7.80
- LSTA $2.41
- Analyst Decision
- FGEN Strong Buy
- LSTA Strong Buy
- Analyst Count
- FGEN 1
- LSTA 2
- Target Price
- FGEN $250.00
- LSTA $23.50
- AVG Volume (30 Days)
- FGEN 61.0K
- LSTA 56.7K
- Earning Date
- FGEN 08-05-2025
- LSTA 08-11-2025
- Dividend Yield
- FGEN N/A
- LSTA N/A
- EPS Growth
- FGEN N/A
- LSTA N/A
- EPS
- FGEN N/A
- LSTA N/A
- Revenue
- FGEN $6,996,000.00
- LSTA $1,000,000.00
- Revenue This Year
- FGEN N/A
- LSTA N/A
- Revenue Next Year
- FGEN N/A
- LSTA N/A
- P/E Ratio
- FGEN N/A
- LSTA N/A
- Revenue Growth
- FGEN N/A
- LSTA N/A
- 52 Week Low
- FGEN $4.50
- LSTA $1.87
- 52 Week High
- FGEN $38.25
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- FGEN 67.08
- LSTA 45.37
- Support Level
- FGEN $7.03
- LSTA $2.49
- Resistance Level
- FGEN $5.73
- LSTA $3.09
- Average True Range (ATR)
- FGEN 0.57
- LSTA 0.26
- MACD
- FGEN 0.35
- LSTA -0.04
- Stochastic Oscillator
- FGEN 100.00
- LSTA 26.50
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.